Etiopathogenesis and Treatment Strategies of Oral Submucous Fibrosis
Tapasya Vaibhav Karemore, Vaibhav Karemore
Abstract
Tapasya Vaibhav Karemore, Vaibhav Karemore
Abstract
The etiopathogenesis and management of oral submucous fibrosis has been the subject of controversy ever since Schwartz first described the condition in 1952. Population estimates of OSMF indicated that 2.5 million people were affected worldwide. This number has risen to 5 million on the Indian subcontinent itself. It calls for the need to treat such a critical precancerous condition with aggressive steps. Before one goes to treat this disease it is required to have a look at all the modalities tried so far in the literature. This article aimed at the same signature facts of the etiopathogenesis and various treatment modalities of OSMF.
OpenAlex reports 20 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The etiopathogenesis and management of oral submucous fibrosis has been the subject of controversy ever since Schwartz first described the condition in 1952. Population estimates of OSMF indicated that 2.5 million people were affected worldwide. This number has risen to 5 million on the Indian subcontinent itself. It calls for the need to treat such a critical precancerous condition with aggressive steps. Before one goes to treat this disease it is required to have a look at all the modalities tried so far in the literature. This article aimed at the same signature facts of the etiopathogenesis and various treatment modalities of OSMF.
Key concepts: Medicine, Oral submucous fibrosis, Dermatology, Fibrosis, Gastroenterology, Internal medicine